GlassScriptPhysician profile
Emily G Womack
NPI 1326300989
$4,108.90
in general payments reported to CMS, 2019-2025
34 companies · $650 in 2025
The $650 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $337 · 2021: $727 · 2022: $924 · 2023: $571 · 2024: $275 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.53 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $827.15 | 2019-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Daiichi Sankyo INC. | $702.23 | 2019-2025 | Injectafer |
| Pfizer INC. | $242.45 | 2019-2025 | |
| Lupin INC. | $240.52 | 2019-2021 | |
| Astellas Pharma US INC | $183.52 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $181.02 | 2020-2025 | Slynd |
| Evofem Biosciences, INC. | $157.56 | 2020-2024 | Phexxi |
| Sumitomo Pharma America, INC. | $155.74 | 2023-2025 | Myfembree, Gemtesa |
| Davol INC. | $128.60 | 2022-2025 | Surgiphor |
| Aspira Women'S Health INC | $122.43 | 2022 | |
| Mayne Pharma Commercial LLC | $106.25 | 2022-2025 | |
| Sage Therapeutics, LLC | $96.08 | 2024-2025 | Zurzuvae |
| Avion Pharmaceuticals | $84.84 | 2020-2021 | |
| Organon LLC | $84.77 | 2021-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $74.98 | 2024-2025 | Myosure Tissue Removal Device, Novasure, Fluent Fluid Management System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $73.98 | 2025 | Clottriever Bold Catheter |
| Myriad Women'S Health, INC. | $68.95 | 2023 | Myrisk |
| Amag Pharmaceuticals, INC. | $68.16 | 2019 | |
| Ethicon US, LLC | $61.11 | 2019-2022 | |
| Therapeuticsmd, INC. | $57.95 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.62 | 2019-2020 | |
| Duchesnay USA Incorporated | $49.34 | 2019 | |
| Lilly USA, LLC | $49.09 | 2025 | Zepbound |
| Novo Nordisk INC | $42.60 | 2023 | Wegovy |
| Scynexis, INC. | $35.02 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $27.44 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $24.01 | 2025 | Qelbree |
| Dexcom, INC. | $21.35 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $16.93 | 2025 | Ligasure |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.95 | 2025 | Xifaxan |
| Millicent US INC | $14.07 | 2024 | Intrarosa, Femring |
| Medicem INC. | $13.66 | 2020 | |
| Amgen INC. | $13.45 | 2021 | |
| Merck Sharp & Dohme LLC | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Womack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.